Olanzapine in the treatment of pervasive developmental disorders: a case series analysis

Olanzapine in the treatment of pervasive developmental disorders: a case series analysis

PDF

J Psychiatry Neurosci 2004;29(1):57-60

Chrissoula Stavrakaki, MD, PhD; Ruxandra Antochi, MD; Patricia C. Emery, BA(Hons)

Stavrakaki — Department of Psychiatry, University of Ottawa, and Child and Family Psychiatric Unit, Children’s Hospital of Eastern Ontario; Antochi — Child and Family Psychiatric Unit, Children’s Hospital of Eastern Ontario; Emery — School of Psychology, University of Ottawa, Ottawa, Ont.

Abstract

Controlling the symptoms that are characteristic of patients with pervasive developmental disorders is often challenging. We report on the safety and efficacy of olanzapine in the treatment of 7 patients with pervasive developmental disorders. The patients were all male and ranged in age from 8 to 52 years. They received olanzapine doses of 5–10 mg/d along with their various other drug regimens. Patients were monitored and evaluated for a mean duration of 17.7 (range 12–26) months while on olanzapine therapy. Very few side effects were observed during treatment. All patients showed clinically significant improvement on the Clinical Global Impressions scale, as well as an improved score as measured by the Global Assessment of Functioning scale. Our observations support the use of long-term olanzapine therapy for symptom control in patients with pervasive developmental disorders.

Résumé

Il est souvent difficile de soulager les symptômes caractéristiques des patients atteints de troubles de développement profonds. Nous présentons un compte rendu de l’innocuité et l’efficacité de l’olanzapine pour le traitement de sept patients ayant des troubles de développement profonds. Les patients étaient tous de sexe masculin et avaient entre 8 et 52 ans. Ils ont reçu des doses d’olanzapine de 5 à 10 mg/j en plus de leurs divers régimes médicamenteux. Ils ont été surveillés et évalués en moyenne pendant 17,7 (entre 12 et 26) mois pendant leur traitement à l’olanzapine. Très peu d’effets secondaires ont été observés au cours du traitement. Tous les patients ont montré des améliorations importantes sur le plan clinique d’après l’échelle d’impression clinique globale. Leurs résultats se sont aussi améliorés sur l’échelle d’évaluation globale du fonctionnement. Nos observations appuient le recours à un traitement à l’olanzapine à long terme pour soulager les symptômes des patients atteints de troubles de développement profonds.


Medical subject headings: antipsychotic agents; child development disorders, pervasive; dopamine; serotonin.

Submitted Sept. 11, 2002; Revised Dec. 18, 2002; Accepted May 20, 2003.

Acknowledgements: We gratefully acknowledge the nonremunerated help of Shannon Muldrew, MA, C. Psych. Assoc., Neuroscience Specialty Representative, Eli Lilly Canada, and Sherilyn G. Walker, BPHE (Hons), Regional Research Associate, Neuroscience Eli Lilly Canada.

Competing interests: None declared.

Correspondence to: Dr. Chrissoula Stavrakaki, Child and Family Psychiatric Unit, Children’s Hospital of Eastern Ontario, 311 McArthur Ave., Suite 200, Ottawa ON K1L 8M3; fax 613 738-4891; csgm91@rogers.com